Clinical Trials
63
33 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
32
50.8%
Completed
4
6.3%
Enrolling By Invitation
1
1.6%
Recruiting
19
30.2%
Suspended
1
1.6%
Terminated
6
9.5%
No approval data available
- DelveInsight's 2025 pipeline analysis reveals 8+ key companies are developing 10+ novel Graves Disease treatment therapies across various clinical development phases. - Recent regulatory milestones include Amgen's TEPEZZA approval by UK MHRA for thyroid eye disease and FDA's breakthrough therapy designation for Viridian's veligrotug. - Emerging therapies targeting IGF-1R pathway show clinical promise, with Sling Therapeutics' linsitinib demonstrating favorable safety profile in over 900 patients across 15 trials. - Pipeline includes diverse therapeutic approaches spanning monoclonal antibodies, small molecules, and gene therapy with multiple routes of administration under investigation.
- Several companies are actively developing novel therapies for Graves' Disease, targeting mechanisms like IGF-1R and FcRn. - Clinical trials are underway for Batoclimab (Phase III), VRDN-001 (Phase III), and Linsitinib (Phase II/III) to address Graves' Disease. - The Graft-versus-Host Disease pipeline includes over 65 drugs in development, with companies like MaaT Pharma and Syndax Pharmaceutical leading the way. - Therapies like MaaT013 and axatilimab are in advanced stages of clinical trials, offering potential new treatments for Graft-versus-Host Disease.
